コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ve ion mode in normal tissue relative to the diseased tissue.
2 ecific Treg and Tconv cells were enriched in diseased tissue.
3 eagents targeting intracellular processes in diseased tissue.
4 e medicine holds great promise for repair of diseased tissue.
5 in biological properties between normal and diseased tissue.
6 the characteristic amyloid fibrils found in diseased tissue.
7 multipotent stem cells to regenerate lost or diseased tissue.
8 ficant difference between the normal and the diseased tissue.
9 detect pathogenic microbes in primary human-diseased tissue.
10 sts, which also stain positively for CD68 in diseased tissue.
11 ailed comparison of proteins from normal and diseased tissue.
12 accumulated in a periductal distribution in diseased tissue.
13 tch-3 expression appeared to be increased in diseased tissue.
14 all vessels within the portal tract septa of diseased tissue.
15 cellular biological processes in normal and diseased tissue.
16 and functional contrast between healthy and diseased tissue.
17 IL-6 production by fibroblasts derived from diseased tissue.
18 rting a greater proportion of osteoid in the diseased tissue.
19 te to the deficiency of nNOS activity in the diseased tissue.
20 lymer chains to favour their accumulation in diseased tissue.
21 mechanotransductive processes in normal and diseased tissue.
22 we aim to study the molecular signature of a diseased tissue.
23 stered nanomaterials and prevent delivery to diseased tissue.
24 s as well as in infiltrating immune cells in diseased tissue.
25 IHC, and ELISA in all samples of healthy and diseased tissue.
26 cular targets of disease are isolated in the diseased tissue.
27 racellular matrix or to deliver a payload to diseased tissue.
28 action and show that pHLIP can target acidic diseased tissue.
29 iver nanoparticles to the endothelium of the diseased tissue.
30 atment hemispherectomy, allowing sampling of diseased tissue.
31 as a stimulus for targeted drug delivery to diseased tissue.
32 time and are able to actively migrate to the diseased tissue.
33 mical analysis of crystallized structures in diseased tissue.
34 1 human and 89 mouse tissue types, including diseased tissue.
35 s known about NeuPSA expression in normal or diseased tissues.
36 individual subjects, including of normal and diseased tissues.
37 en therapies that will regenerate and repair diseased tissues.
38 utic and imaging agents to select organs and diseased tissues.
39 evelopment is selectively targeting drugs to diseased tissues.
40 ive properties that accumulate in normal and diseased tissues.
41 y of other imaging and therapeutic agents to diseased tissues.
42 overcome the issues of harvesting cells from diseased tissues.
43 ent for this cellular treatment strategy for diseased tissues.
44 nd proliferations driven by an Ag present in diseased tissues.
45 en proteases and their cognate inhibitors in diseased tissues.
46 t also disrupts vascular barrier function in diseased tissues.
47 NA-seq data from diverse types of normal and diseased tissues.
48 late monocyte adhesion and infiltration into diseased tissues.
49 man CD40, which is expressed by a variety of diseased tissues.
50 proteomes and their dynamics in healthy and diseased tissues.
51 ng vectors specific for endothelial cells in diseased tissues.
52 y effective for molecularly "fingerprinting" diseased tissues.
53 ivery of radioisotopes or chemical agents to diseased tissues.
54 vely proteinase-resistant isoform (PrPSc) in diseased tissues.
55 s for the delivery of therapeutic genes into diseased tissues.
56 ne structural parameters were altered in all diseased tissues.
57 d in cultured cells as well as in normal and diseased tissues.
58 ation that have been observed in Zn(2+)-rich diseased tissues.
59 s does not accurately reflect what occurs in diseased tissues.
60 o be expressed, with few exceptions, only in diseased tissues.
61 pression of specific nucleic acid sensors in diseased tissues.
62 ted by unfavorable environments in aging and diseased tissues.
63 ssion of these cytokine mRNAs in healthy and diseased tissues.
64 f fundamental questions about the genomes of diseased tissues.
65 tanding the function of cells in healthy and diseased tissues.
66 the enrichment of cell subset signatures in diseased tissues.
67 ministration allows for direct access to the diseased tissues.
68 is drives blood vessel growth in healthy and diseased tissues.
69 ed drugs and structure-specific targeting to diseased tissues.
70 manner, thereby promoting arteriogenesis in diseased tissues.
71 Etiology drives progenitor fate within diseased tissues.
72 fine their physiological roles in normal and diseased tissues.
73 hage consortia differed between bleached and diseased tissues.
74 een a cell and its environment in intact and diseased tissues.
75 inimizing off-target interactions toward non-diseased tissues.
76 y tissues compared with bleached portions of diseased tissues.
77 growth can be exploited in treating aged and diseased tissues.
78 ggers massive metabolic reprogramming in the diseased tissues.
79 rol recruitment of pathogenic lymphocytes in diseased tissues.
80 ical roles of sodium channels in healthy and diseased tissues.
81 y of glucocorticoid signaling in healthy and diseased tissues.
82 veloping agents to target the endothelium in diseased tissues.
83 ge-scale studies of chromatin from normal or diseased tissues.
85 and mean IL-6 concentrations were highest in diseased tissues adjacent to >6 mm sulci and were signif
87 n is in the protein that is deposited in the diseased tissue and in these cases the whole protein is
88 ides contrast enhancement between normal and diseased tissue and microscopic imaging that provides ti
90 bably opportunistic colonizers of previously diseased tissue and others which are unique species.
91 f the presence of Mig in any human normal or diseased tissue and the first description of IP-10 in ce
92 in healthy cells differs from that found in diseased tissue and, if so, whether glycosylation affect
93 d characterization of gene expression within diseased tissues and circulating cells from animal model
94 enerically applicable for targeting cells to diseased tissues and elucidating the biology of cell-cel
95 requently isolated bacteria in periodontally diseased tissues and is reported to synergize with Pg, e
97 of synthetic implants in the restoration of diseased tissues and organs is to use inert and solid ma
101 e complex mechanisms of crystal formation in diseased tissues and their interplay with the nutrients,
102 ing, pHLIP has utility as an agent to target diseased tissues and translocate molecules through the m
103 umber of functional progenitors delivered to diseased tissue, and prevents correction of underlying p
104 ly occurring differences between healthy and diseased tissues, and active targeting, which utilizes v
105 f Kv1.3(high) expressing cells in normal and diseased tissues, and to visualize the distribution of f
106 ondrial proteomics data sets from normal and diseased tissue are published, MitoMiner can be used to
108 ies when the differences between healthy and diseased tissues are small; clinically, CT image noise i
109 ric to quantifiably differentiate normal and diseased tissues based on the physical properties of the
111 he measurement of MAO activity in normal and diseased tissues, blood samples, and other biological fl
112 idative stress and apoptosis are nitrated in diseased tissues but not in normal tissues; definitive e
113 used in strategies to regenerate and repair diseased tissues, but current therapies that go directly
114 ma delta + T cells were found in half of the diseased tissues, but in none of the healthy tissues of
115 nd imaging are designed to accumulate in the diseased tissue by exploiting the Enhanced Permeability
117 ing, targeting, and possibly treating acidic diseased tissue by using the selective insertion and fol
118 to their potential for replacing damaged and diseased tissues by differentiating into tissue-specific
119 -gradient echo magnetic resonance imaging in diseased tissues can shed light on the pathological proc
120 d IFN-alpha mRNA was significantly higher in diseased tissues compared to healthy tissues in patients
123 , IL-31 receptor expression was increased in diseased tissues derived from an animal model of airway
125 o an imaging agent, to select patients whose diseased tissues display sufficient targeted receptors f
126 ling of the fibronectin matrix in injured or diseased tissue elicits an EDA-dependent fibro-inflammat
127 therapeutic cells are incapable of targeting diseased tissues following systemic infusion, which repr
130 datasets as input: an expression dataset of diseased tissues from patients with a disease of interes
131 ly relevant protein processing in normal and diseased tissue-from 40 to 70% of proteins also occur in
133 itor cells for the restoration of injured or diseased tissues has garnered much interest recently, es
134 though genome-wide transcriptome analysis on diseased tissues has greatly advanced our understanding
135 decoy receptor osteoprotegerin, measured in diseased tissue homogenates were significantly higher in
136 ilar concentration pattern within normal and diseased tissue; however, the concentration pattern of I
137 identify the sequences of microorganisms in diseased tissues, i.e., to identify organisms that appea
138 TRAF proteins are expressed in normal and diseased tissue in a regulated fashion, suggesting that
139 the central nervous system and for repair of diseased tissue in conditions such as Parkinson's diseas
141 ve ions inside a cell in vitro, and inside a diseased tissue in vivo, may indicate growth or recurren
142 fferentially transcribed between healthy and diseased tissues in colorectal cancer and chronic lympho
144 key to find novel avenues for CO delivery to diseased tissues in need of treatment, without concomita
145 and imaging MS has been applied to multiple diseased tissues, including human non-small cell lung tu
146 , protein, and activity levels in normal and diseased tissues indicate targeting applicability in a v
148 tral sensitivity, and selective targeting to diseased tissue make DENAQ a prime drug candidate for vi
149 Endogenous cues that are increased in the diseased tissue may amplify the activity of CD4(+)CD28(-
151 esses through the engineering of healthy and diseased tissue models towards the treatment of hypoxia-
154 ted antigenic stimulation and are present in diseased tissues of patients with various autoimmune dis
155 sed gene expression libraries from normal or diseased tissues offer opportunities to interrogate cell
156 ncrease in the interstitial water within the diseased tissue or a change in the vibrational modes of
157 d plasma) and others in the proximity of the diseased tissue or cell (e.g. bile, urine, and sputum) o
158 how do human eosinophils become activated in diseased tissues or at the site of an immune response?
159 profiling technologies to compare normal and diseased tissues or to assess molecular alterations resu
161 d to image wound healing in other injured or diseased tissues, or to monitor tissue changes over time
163 (ECM) in directing cell fate in healthy and diseased tissues--particularly in development, wound hea
164 infiltration of different pancreaticobiliary diseased tissues (PDAC, ampullary carcinoma, cholangioca
165 population of patients, DCs recruited at the diseased tissue produce high levels of CCL-2 and IL-8 an
166 ve pharmacodelivery of cytotoxic payloads to diseased tissues, providing an innovative platform in ch
167 oor efficiency of nanomaterial delivery into diseased tissues, redistribution of nanomaterials within
168 teomic study of human glaucoma may represent diseased tissue-related antigens and serve as candidate
172 performed, PCR products were sequenced, and diseased tissue samples were studied for intercellular j
176 been identified in periodontal disease, and diseased tissues showed elevated RANKL mRNA expression,
177 ription that will deliver radiation doses to diseased tissues sufficient to produce an effective trea
178 tylation in our studies was only detected in diseased tissue, suggesting it may have a role in pathol
179 ins was highly restricted in both normal and diseased tissues, suggesting defined physiological roles
180 resolution downloadable images of normal and diseased tissues that are searchable through orthogonal
181 nment is an integral component of normal and diseased tissues that is poorly understood owing to its
185 which intimately interacts with healthy and diseased tissues through resident and recruited leukocyt
186 fying protein differences between normal and diseased tissue, thus providing the opportunity to searc
187 w top-down strategy for directly employing a diseased tissue to produce biofunctional nanovesicle-bas
188 s, reactive vasculature forms in response to diseased tissues to create new niches that secrete CXCL1
191 he expression of TCC isoforms in healthy and diseased tissue was investigated using quantitative real
193 onal skin as exemplar T(H)2 and T(H)1/T(H)17 diseased tissue, we sought to clarify common and unique
194 f placenta, hemangioma, and eight normal and diseased tissues were compared by hierarchical and nonhi
196 ace of the nanoparticle and molecules in the diseased tissue, while minimizing off-target interaction
197 issue engineering aims to replace damaged or diseased tissue with a functional regenerate that restor
198 ents with TMJ disorders an option to replace diseased tissue with autologous, functional tissue.
200 enabling discrimination between healthy and diseased tissue, with the cell-killing ability of cytoto
201 ical epithelium or in stroma adjacent to the diseased tissues, with cellular proliferation and extrac
202 e examination of a variety of developing and diseased tissues, with specific focus on the dynamics of
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。